Effect of initial body mass index on survival outcome of patients with myelodysplastic syndrome: a single-center retrospective study

References

• Soderberg KC, Kaprio J, Verkasalo PK, et al. Overweight, obesity and risk of haematological malignancies: a cohort study of Swedish and Finnish twins. Eur J Cancer. 2009;45:1232–1238.
   PubMed Web of Science ®Google Scholar
• Lichtman MA. Obesity and the risk for a hematological malignancy: leukemia, lymphoma, or myeloma. Oncologist. 2010;15:1083–1101.
   PubMed Web of Science ®Google Scholar
• MacInnis RJ, English DR, Hopper JL, et al. Body size and composition and the risk of lymphohematopoietic malignancies. J Natl Cancer Inst. 2005;97:1154–1157.
   PubMed Web of Science ®Google Scholar
• Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–1638.
   PubMed Web of Science ®Google Scholar
• Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569–578.
   PubMed Web of Science ®Google Scholar
• Bhaskaran K, Douglas I, Forbes H, et al. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults. Lancet. 2014;384:755–765.
   PubMed Web of Science ®Google Scholar
• Kumar M, Nooka A, Langston A, et al. Impact of body mass index (BMI) on overall survival in myeloma. Blood. 2012;120:4289–4289.
   Google Scholar
• Landgren O, Andren H, Nilsson B, et al. Risk profile and outcome in Hodgkin’s lymphoma: is obesity beneficial? Ann Oncol. 2005;16:838–840.
   PubMed Web of Science ®Google Scholar
• Jones JA, Fayad LE, Elting LS, et al. Body mass index and outcomes in patients receiving chemotherapy for intermediate-grade B-cell non-Hodgkin lymphoma. Leuk Lymphoma. 2010;51:1649–1657.
   PubMed Web of Science ®Google Scholar
• Carson KR, Bartlett NL, McDonald JR, et al. Increased body mass index is associated with improved survival in United States veterans with diffuse large B-cell lymphoma. J Clin Oncol. 2012;30:3217–3222.
   PubMed Web of Science ®Google Scholar
• Liu J, Deng YT, Zhang L, et al. Body mass index as a prognostic factor in patients with extranodal natural killer/T-cell lymphoma, nasal type. Oncotarget. 2016;7:78159–78167.
   PubMed Web of Science ®Google Scholar
• Li YJ, Yi PY, Li JW, et al. Increased body mass index is associated with improved overall survival in extranodal natural killer/T-cell lymphoma, nasal type. Oncotarget. 2017;8:4245–4256.
   PubMed Web of Science ®Google Scholar
• Tarella C, Caracciolo D, Gavarotti P, et al. Overweight as an adverse prognostic factor for non-Hodgkin’s lymphoma patients receiving high-dose chemotherapy and autograft. Bone Marrow Transplant. 2000;26:1185–1191.
   PubMed Web of Science ®Google Scholar
• Geyer SM, Morton LM, Habermann TM, et al. Smoking, alcohol use, obesity, and overall survival from non-Hodgkin lymphoma: a population-based study. Cancer. 2010;116:2993–3000.
   PubMed Web of Science ®Google Scholar
• Hong F, Habermann TM, Gordon LI, et al. The role of body mass index in survival outcome for lymphoma patients: US intergroup experience. Ann Oncol. 2014;25:669–674.
   PubMed Web of Science ®Google Scholar
• Brunner AM, Sadrzadeh H, Feng Y, et al. Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia. Am J Hematol. 2013;88:642–646.
   PubMed Web of Science ®Google Scholar
• Medeiros BC, Othus M, Estey EH, et al. Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia. Haematologica. 2012;97:1401–1404.
   PubMed Web of Science ®Google Scholar
• Kempf E, Hirsch P, Labopin M, et al. Prognosis of body mass index and chemotherapy dose capping in acute myeloid leukaemia. Leuk Res. 2014;38:1425–1429.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Licht AS, Hyland AJ, et al. Is obesity a prognostic factor for acute myeloid leukemia outcome? Ann Hematol. 2012;91:359–365.
   PubMed Web of Science ®Google Scholar
• Lin A, Othus M, McQuary A, et al. Influence of obesity on efficacy and toxicity of induction chemotherapy in patients with newly diagnosed acute myeloid leukemia. Leuk Lymphoma. 2013;54:541–546.
   PubMed Web of Science ®Google Scholar
• Butturini AM, Dorey FJ, Lange BJ, et al. Obesity and outcome in pediatric acute lymphoblastic leukemia. J Clin Oncol. 2007;25:2063–2069.
   PubMed Web of Science ®Google Scholar
• Heiblig M, Elhamri M, Nicolini FE, et al. Effect of initial body mass index on survival outcome of patients with acute leukemia: a single-center retrospective study. Clin Lymphoma Myeloma Leuk. 2015;15:S7–S13.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol. 2012;87:692–701.
   PubMed Web of Science ®Google Scholar
• Ma X, Lim U, Park Y, et al. Obesity, lifestyle factors, and risk of myelodysplastic syndromes in a large US cohort. Am J Epidemiol. 2009;169:1492–1499.
   PubMed Web of Science ®Google Scholar
• Murphy F, Kroll ME, Pirie K, et al. Body size in relation to incidence of subtypes of haematological malignancy in the prospective Million Women Study. Br J Cancer. 2013;108:2390–2398.
   PubMed Web of Science ®Google Scholar
• Poynter JN, Richardson M, Blair CK, et al. Obesity over the life course and risk of acute myeloid leukemia and myelodysplastic syndromes. Cancer Epidemiol. 2016;40:134–140.
   PubMed Web of Science ®Google Scholar
• Mishra A, Rollison D, Ali A, et al. Obesity is poor prognostic factor in lower risk myelodysplastic syndrome. Blood. 2011;118:5018–5018.
   Google Scholar
• Brunning RD, Orazi A, Germing U, et al. Myelodysplastic syndromes/neoplasms, overview. In: Swerdlow SH, Campo E, Harris NL, et al. editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC; 2008. p. 88–93.
   Google Scholar
• Della Porta MG, Malcovati L, Strupp C, et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica. 2011;96:441–449.
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–2465.
   PubMed Web of Science ®Google Scholar
• World Health Organization: Global Database on Body Mass Index. [Cited 2017 Jan 20] Available from: http://apps.who.int/bmi/index.jsp?introPage=intro_3.html
   Google Scholar
• Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419–425.
   PubMed Web of Science ®Google Scholar
• Hunter RJ, Navo MA, Thaker PH, et al. Dosing chemotherapy in obese patients: actual versus assigned body surface area (BSA). Cancer Treat Rev. 2009;35:69–78.
   PubMed Web of Science ®Google Scholar
• Rodvold KA, Rushing DA, Tewksbury DA. Doxorubicin clearance in the obese. J Clin Oncol. 1988;6:1321–1327.
   PubMed Web of Science ®Google Scholar
• Sparreboom A, Wolff AC, Mathijssen RH, et al. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol. 2007;25:4707–4713.
   PubMed Web of Science ®Google Scholar
• Henninger C, Huelsenbeck S, Wenzel P, et al. Chronic heart damage following doxorubicin treatment is alleviated by lovastatin. Pharmacol Res. 2015;91:47–56.
   PubMed Web of Science ®Google Scholar
• Malcovati L. Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. Leuk Res. 2007;31:S2–S6.
   PubMed Web of Science ®Google Scholar
• Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. JCO. 2005;23:7594–7603.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Malcovati L. Myelodysplastic syndromes-coping with ineffective hematopoiesis. N Engl J Med. 2005;352:536–538.
   PubMed Web of Science ®Google Scholar
• Hino M, Nakao T, Yamane T, et al. Leptin receptor and leukemia. Leuk Lymphoma. 2000;36:457–461.
   PubMed Web of Science ®Google Scholar
• Uddin S, Mohammad RM. Role of leptin and leptin receptors in hematological malignancies. Leuk Lymphoma. 2016;57:10–16.
   PubMed Web of Science ®Google Scholar
• Konopleva M, Mikhail A, Estrov Z, et al. Expression and function of leptin receptor isoforms in myeloid leukemia and myelodysplastic syndromes: proliferative and anti-apoptotic activities. Blood. 1999;93:1668–1676.
   PubMed Web of Science ®Google Scholar